PRINCETON, N.J., Nov. 2 PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Jeffrey Trotter has joined the Company as Executive Vice President, Phase IV Development. In his role, he will provide leadership for the Company's Phase IV operations and its global expansion.
"We are very pleased to have Jeff Trotter join PharmaNet," commented Jeffrey P. McMullen, president and chief executive officer. "His depth of experience and pioneering approaches to patient registries, health economics and outcomes research will enable us to expand our services to clients seeking to undertake the full range of peri-approval research programs."
Mr. McMullen continued, "Phase IV services continue to be a growth opportunity for PharmaNet. I am confident we can strengthen our presence to become the definitive choice for research excellence in this critical and rapidly changing field."
As an entrepreneur, researcher, consultant and industry leader, Jeffrey Trotter has been an innovator in the evolving outcomes research community, most recently providing strategic and operational direction to pharmaceutical and device companies on the importance of 'real world' clinical research, observational studies and patient registries. Mr. Trotter was founder and president of Ovation Research Group, one of the leading independent research and consulting organizations providing health economics and outcomes research for pharmaceutical and medical device companies. Ovation became known worldwide for its industry-leading perspectives on patient registries, clinical studies fulfilling a broad continuum of needs ranging from product commercialization to safety surveillance and risk management. Having sold Ovation, Jeff joins PharmaNet Development Group from his independent consultancy, J. Trotter Research and Consulting.
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.
Contact: Anne-Marie Hess Phone: (609) 951-6842 Email: email@example.com
SOURCE PharmaNet Development Group